Britol-Myers Squibb will return an early-stage cancer drug, which could have translated into $315 million in bio bucks plus sales performance milestones and double-digit royalties, to South San Francisco-based Exelixis (NASDAQ: EXEL).
Exelixis — now concentrating on cabozantinib, a drug that BMS gave back little more than a year ago — said it has no plans to further research and development or eventually commercialize the drug.
A bummer? Yeah, probably. A lost opportunity? Maybe. A total loss? No.
No comments:
Post a Comment